|
|
|
| WEDNESDAY, MAY
8, 2002 |
| 08:30 - 09:20 |
|
|
| PLENARY SESSION 3: SALPETER LECTURE |
| Chairperson: |
U.J. McMahan, USA |
|
| 08:30 |
CHEMICAL
KINETICS PARAMETERS AND RECEPTOR DEGRADATION RATES AT THE NEUROMUSCULAR
JUNCTION
E.E. Salpeter, USA |
| 09:20 - 10:40 |
|
|
| SESSION 10 |
| Chairperson: |
S. Fuchs, Israel |
|
| 09:20 |
CONGENITAL
MYASTHENIC SYNDROMES (CMS): MULTIPLE MOLECULAR TARGETS AT THE NEUROMUSCULAR
JUNCTION
A.G. Engel, K. Ohno, S.M. Sine, USA |
| 09:40 |
ANTIBODIES
TO ACETYLCHOLINE RECEPTORS AND MUSK IN MYASTHENIA GRAVIS AND RELATED
DISORDERS
A. Vincent, UK |
| 10:00 |
INHIBITORY
EFFECTS OF MUSCARINIC RECEPTOR AUTOANTIBODIES ON PARASYMPATHETIC
NEUROTRANSMISSION IN SJOGREN'S SYNDROME
S.A. Waterman, S. Lester, T.P. Gordon, M. Rischmueller, Australia
|
| 10:20 |
IMMUNOTHERAPY
OF MYASTHENIA GRAVIS: ANTIGEN-SPECIFIC MUCOSAL TOLERANCE AND ANTAGONISTS
OF KEY CYTOKINES AND COSTIMULATORY FACTORS
M.C. Souroujon, S-H. Im, S. Fuchs, Israel |
| 10:40 |
THE
ALPHA7 NACHR L250T MUTATION IN MICE: A MODEL FOR EPILEPSY IN MEN
A. Orr-Urtreger, R.A. Sack, M. Kedmi, A. Harmelin, Z. Gil,
Israel |
| |
Coffee Break and Poster
Viewing |
| 11:10 - 12:50 |
|
|
| SESSION 11 |
| Chairperson: |
N.C. Inestrosa, Chile |
|
| 11:10 |
NEURODEGENERATIVE PROCESSES
IN ALZHEIMER'S DISEASE
N.C. Inestrosa, G.V. De Ferrari, J.L. Garrido, A. Alvarez,
M. Bronfman, Chile |
| 11:30 |
ACETYLCHOLINESTERASE
FACILITATES AMYLOID DEPOSITION N A MOUSE MODEL OF ALZHEIMER'S DISEASE
T. Rees, P. Hammond, S. Younkin, H. Soreq, S. Brimijoin,
USA, Israel |
| 11:50 |
ACETYLCHOLINE
HYDROLYSIS AT THE MAMMALIAN SKELETAL NEUROMUSCULAR JUNCTION: MORE
THAN ONE ENZYME
E. Krejci, J. Minic, J. Molgo, France |
| 12:10 |
MOLECULAR
AND FUNCTIONAL DIVERSITY IN NICOTINIC ACETYLCHOLINE RECEPTOR GENE
FAMILIES OF C. ELEGANS AND D. MELANOGASTER
D.B. Sattelle, UK |
| 12:30 |
GENETIC DISSECTION OF AN
ACETYLCHOLINE RECEPTOR INVOLVED IN NEURONAL DEGENERATION
M. Treinin, S. Halevi, L. Yassin, Israel |
| 12:50 |
Lunch Break and Poster
Viewing |
| 14:15 - 15:55 |
|
|
| SESSION 12 |
| Chairperson: |
V.I. Tsetlin, Russia |
|
| 14:15 |
NEURONAL
NICOTINIC RECEPTORS, ALLOSTERIC POTENTIATING LIGANDS (apls), AND
ENDOGENOUS METABOLITES: IMPLICATIONS FOR TREATMENT OF ALZHEIMER'S
DISEASE (AD)
E.X. Albuquerque, M.D. Santos, M. Alkondon, E.K. Moon, A.
Maelicke, USA, Brazil, Germany |
| 14:35 |
THE
RATIONALE FOR USING GALANTAMINE TO TREAT DIFFERENT DEMENTIA TYPES
A. Maelicke, S. Lilienfeld, C. Grantham, Germany, USA, Belgium
|
| 14:55 |
PREVENTION
OF APOPTOSIS BY GALANTAMINE: A NOVEL THERAPEUTIC STRATEGY FOR ALZHEIMER’S
DISEASE?
M.G. Lopez, E. Arias, E. Ales, A.G. Garcia, Spain |
| 15:15 |
PRECLINICAL
STUDIES OF GALANTAMINE USING A FORM OF ASSOCIATIVE LEARNING SEVERELY
IMPAIRED IN ALZHEIMER’S DISEASE
D.S. Woodruff-Pak, USA |
| 15:35 |
A
COMMON AGONIST AND POTENTIATOR FOR ALPHA7 NICOTINIC
5-HT3 SEROTONIN RECEPTORS
R. Zwart, L. Broad, C. Felhouse, K. Pearson, G. McPhie, E.
Sher, UK |
| 16:30 - 17:50 |
|
|
| SESSION 13 |
| Chairperson: |
U. Littauer, Israel |
|
| 16:30 |
MOLECULAR BIOLOGY OF ALZHEIMER’S
DISEASE - THERAPEUTIC PERSPECTIVES
R. Nitsch, Switzerland |
| 16:50 |
BETA-AMYLOIDS,
TAU HYPERPHOSPHORYLATION AND COGNITION ARE BENEFICIALLY AFFECTED
BY M1 MUSCARINIC AGONISTS - PERSPECTIVES IN ALZHEIMER'S DISEASE
TREATMENT
A. Fisher, Z. Pittel, R. Brandeis, R. Haring, N Bar-Her,
H. Sonego,
I. Marcovitch, N. Natan, N. Maestre-Frances, N. Bons, Israel, France
|
| 17:10 |
CHOLINERGIC
DEFICITS AND NON-COGNITIVE BEHAVIOURAL CHANGES IN PATIENTS WITH
DEMENTIA
P. Francis, C.P.L-H. Chen, M.M. Esiri, J. Keene, UK |
| 17:30 |
CROSS-TALK
BETWEEN APOLIPOPROTEIN E THE AMYLOID PRECURSOR PROTEIN AND BRAIN
INFLAMMATION
D.M. Michaelson, S. Meilin, G. Ophir, Y. Ezra, L. Oron, S.M.
Beni,
E. Shohami, Israel |
|
